Skip to main content

and
  1. Article

    Open Access

    Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

    M Chin, J I Sive, C Allen, C Roddie, S J Chavda, D Smith in Blood Cancer Journal (2017)

  2. Article

    Open Access

    A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

    This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Rel...

    R Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, A Nagler, K L Yong in Leukemia (2017)

  3. Article

    Open Access

    Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations

    Multiple myeloma (MM) is a clinically and genetically heterogenous cancer where tumour cells have dysregulated expression of a D-type cyclin, often in association with a recurrent IgH translocation. Patients w...

    J Glassford, D Kassen, J Quinn, C Stengel, K Kallinikou, A Khwaja in Blood Cancer Journal (2012)

  4. No Access

    Article

    Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells

    M Baou, A Jewell, A Muthurania, R G Wickremasinghe, K L Yong, R Carr, P Marsh in Leukemia (2009)

  5. No Access

    Article

    A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer

    We describe a new model of myeloma bone disease in which β2m NOD/SCID mice injected with KMS-12-BM cells develop medullary disease after tail vein administration. Micro-computed tomography analysis demonstrated s...

    N Rabin, C Kyriakou, L Coulton, O M Gallagher, C Buckle, R Benjamin, N Singh in Leukemia (2007)